Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs NXP Semiconductors N.V. Common Stock (NXPI) Price & Performance

Kymera Therapeutics Inc. Common StockTrade
NXP Semiconductors N.V. Common StockTrade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs NXP Semiconductors N.V. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while NXP Semiconductors N.V. Common Stock trades at $217.48 (market cap $57.07B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 6.4× Kymera Therapeutics Inc. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and NXP Semiconductors N.V. Common Stock for 5 Days on average.

KYMRNXPI
Market Cap
$8.87B$57.07B
Volume
779,1073,033,835
Sector
HealthTechnology
52-Week High
$127.31$332.67
52-Week Low
$55.80$184.19
Typical Hold Time
0 Days5 Days
Enterprise Value
$8.26B$65.18B
Dividend Yield
—1.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

NXP Semiconductors N.V. Common Stock

NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.

NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR
100% Buy0% Sell
Avg holding period · 0 Days
NXPI

No sentiment data available yet.

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →

About NXP Semiconductors N.V. Common Stock

NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.

Read more on NXPI →